We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Collaboration to Make Diagnostic Medical Imaging Less Hazardous Using Hyperpolarization Agents

By MedImaging International staff writers
Posted on 23 Oct 2014
Print article
Image: A collaborative effort between EPFL, CNRS, ENS Lyon, CPE Lyon, and ETH Zürich has led to the development of a novel approach that can considerably improve the capabilities of medical imaging with safer procedures for the patient (Photo courtesy of EPFL - Ecole Polytechnique Fédérale de Lausanne).
Image: A collaborative effort between EPFL, CNRS, ENS Lyon, CPE Lyon, and ETH Zürich has led to the development of a novel approach that can considerably improve the capabilities of medical imaging with safer procedures for the patient (Photo courtesy of EPFL - Ecole Polytechnique Fédérale de Lausanne).
A collaborative effort by scientists has led to the development of an innovative strategy that can considerably improve the capabilities of medical imaging with safer procedures for the patient.

Medical imaging is a significant part of healthcare today, with imaging techniques such as magnetic resonance imaging (MRI), computed tomography (CT) scanning, and nuclear magnetic resonance (NMR) increasing greatly over the last 20 years. However, continuing problems of image resolution and quality still hinder these techniques because of the nature of living tissue. A solution is hyperpolarization, which involves injecting the patient with substances that can enhance imaging quality by following the distribution and fate of specific molecules in the body but that can be harmful or potentially toxic to the patient.

A team of scientists from Ecole Polytechnique Fédérale de Lausanne (EPFL; Switzerland), Le Centre National de la Recherche Scientifique (CNRS; Paris, France), ENS Lyon ( École Normale Supérieure de Lyon; France), and CPE Lyon (France), and Swiss Federal Institute of Technology in Zurich (ETH Zürich; Switzerland) has developed a new generation of hyperpolarization agents that can be used to dramatically enhance the signal intensity of imaged body tissues without presenting any danger to the patient. Their research was published September 29, 2014, in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).

The team of scientists coordinated by Dr. Lyndon Emsley, a professor at EPFL and ENS Lyon, has developed a new generation of hyperpolarizing agents that are both effective and safe for the patient. The substances, called HYPSOs, were developed by the teams of Christophe Copéret at ETH Zurich and Chloé Thieuleux at CPE-Lyon. The HYPSOs come in the form of a fine, white, porous powder that contains the “tracking” molecules to be hyperpolarized. The HYPSO powder is comprised of mesoporous silica (silicon dioxide), which is the major component of sand and is commonly used in nanotechnology.

The silica powder used for the HYPSOs consists of particles, containing pore channels. It has been designed in such a way that the surface of each pore channel can be evenly covered with molecules known as “organic radicals.” The radicals are homogeneously distributed, and are able to induce polarization around them. The pore channels are then filled with a solution of the “tracking” molecules to be hyperpolarized, which act as markers for the imaging—e.g., pyruvate, which is important in the production of energy in cells.

Using novel instruments and methods developed by Dr. Sami Jannin at EPFL, the HYPSO sample is hyperpolarized with microwaves in a magnetic field at a very low temperature. The magnetic moments of the atoms are forced to align through a process called “dynamic nuclear polarization,” which transfers the spin energy of the free radicals’ electrons to the markers’ nuclei. The electronic spin magnetism of the hyperpolarizing agent acts on the marker molecule, aligning, or “polarizing,” the nuclei of its atoms.

Hot water is then used to melt and flush the substrate out of the powder. Because of the equipment and conditions needed, the process generally takes place in a room adjacent to the imaging facility. The substrate is then injected through a long tube into the patient inside the medical imaging device. The entire process only lasts about 10 seconds.
Two scans are performed, one with and one without the hyperpolarized agent. When the two images are compared, it is possible to observe the distribution of the hyperpolarized marker in the patient’s body, which, depending on the medical setting, can be indicative of disease. For example, accumulation of pyruvate in the prostate could be an early indication of prostate cancer.

The researchers have evaluated the effectiveness of the HYPSOs technology on several imaging markers, including pyruvate, acetate, fumarate, pure water, and a simple peptide. Because the HYPSOs is physically retained during dissolution, the technique generates pure solutions of hyperpolarized markers, free of any contaminant. The protocol is therefore simpler and potentially safer for the patient, while its dramatic efficiency on signal quality forecasts the use of this new generation of hyperpolarized agents with a broad range of molecules. As Dr. Jannin pointed out, “We have now received queries of scientists from abroad who are eager to boost their research with this new technology. Amongst other plans, we are very excited about testing these materials in vivo.”

Related Links:

Ecole Polytechnique Fédérale de Lausanne
Le Centre National de la Recherche Scientifique
ENS Lyon


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Computed Tomography (CT) Scanner
Aquilion Serve SP
New
Ultrasound Needle Guide
Ultra-Pro II
New
Brachytherapy Planning System
Oncentra Brachy

Print article

Channels

Ultrasound

view channel
Image: Structure of the proposed transparent ultrasound transducer and its optical transmittance (Photo courtesy of POSTECH)

Ultrasensitive Broadband Transparent Ultrasound Transducer Enhances Medical Diagnosis

The ultrasound-photoacoustic dual-modal imaging system combines molecular imaging contrast with ultrasound imaging. It can display molecular and structural details inside the body in real time without... Read more

Nuclear Medicine

view channel
Image: PET/CT of a 60-year-old male patient with clinical suspicion of lung cancer (Photo courtesy of EJNMMI Physics)

Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times

F-18 FDG-PET scans are a way to look inside the body using a special dye, and these scans can be either static or dynamic. Static scans happen 60 minutes after the dye is administered into the body, showing... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: The acquisition will expand IBA’s medical imaging quality assurance offering (Photo courtesy of Radcal)

IBA Acquires Radcal to Expand Medical Imaging Quality Assurance Offering

Ion Beam Applications S.A. (IBA, Louvain-La-Neuve, Belgium), the global leader in particle accelerator technology and a world-leading provider of dosimetry and quality assurance (QA) solutions, has entered... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.